SCHEMBL5025223

SCHEMBL5025223

Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nc(-c2ccncc2)cs1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.73
ABL1 P00519 8/20 0.68
CSF1R P07333 5/20 0.67
KIT P10721 5/20 0.67
EGFR P00533 6/20 0.66
POLB P06746 1/20 0.65
MAPT P10636 1/20 0.65
MAPK1 P28482 1/20 0.65
RAD52 P43351 1/20 0.65
ATM Q13315 1/20 0.65
LYN P07948 3/20 0.64
BCR P11274 3/20 0.64
ERBB2 P04626 1/20 0.64
LCK P06239 1/20 0.64
FYN P06241 1/20 0.64
YES1 P07947 1/20 0.64
HCK P08631 1/20 0.64
PDGFRB P09619 1/20 0.64
FGR P09769 1/20 0.64
PIM1 P11309 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561586 0.97 KIT (0.71) BRAFABL1CSF1RKITEGFR
Hydrochloric Acid SCHEMBL6014047 0.96 KIT (0.70) BRAFABL1CSF1RKITEGFR
SCHEMBL4830586 0.90 KIT (0.77) BRAFABL1CSF1RKITEGFR
SCHEMBL14286285 0.90 ABL1 (0.71) BRAFABL1CSF1RKITEGFR
SCHEMBL13349541 0.88 ABL1 (0.68) BRAFABL1CSF1RKITEGFR
SCHEMBL6431039 0.88 ABL1 (0.70) BRAFABL1CSF1RKITEGFR
SCHEMBL5023760 0.85 ABL1 (0.58) BRAFABL1CSF1RKITEGFR
SCHEMBL715899 0.85 KIT (0.85) BRAFABL1CSF1RKITEGFR
SCHEMBL22024635 0.85 BRAF (0.69) BRAFABL1CSF1RKITEGFR
SCHEMBL22025360 0.85 BRAF (0.69) BRAFABL1CSF1RKITEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US claimed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN claimed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP claimed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO claimed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors AB SCIENCE 2008-02-14 US disclosed
CN-1934107-A 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors AB SCIENCE (FR) 2007-03-21 CN disclosed
EP-1711497-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB Science (FR) 2006-10-18 EP disclosed
WO-2005073225-A1 2-(3-SUBSTITUTED-ARYL)AMINO-4-ARYL-THIAZOLES AS TYROSINE KINASE INHIBITORS AB SCIENCE (FR) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039466-A1 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors KIT, MAP3K2, RET BRAF 35/4885ABL1 22/4885CSF1R 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.